When can oxygen support create time?
Define the window in which immediate oxygen-carrying support may bridge to hemorrhage control, surgery, disease-specific therapy, compatible blood or endogenous erythropoiesis.
A focused evidence map supporting BHOC Veterinary. Use this portal for guided context and developing Concepts & Questions, then continue into Vet Real-World Evidence & Cases for publications and regulatory records.
Return to the Veterinary section for Oxyglobin regulatory records, FDA and EMA sources, and the indexed veterinary publication archive.
Efficacy population: Oxyglobin 20/21 vs control 9/28; p≤0.001. Intent-to-treat: 73% (22/30) vs 29% (10/34).
FDA endpoint: no additional oxygen-carrying support required for 24 hours. This is a treatment-success endpoint, not survival.
Oxyglobin Solution - Case Listing Book II is a manufacturer-collected descriptive archive, not a controlled efficacy trial. It contains 885 veterinary reports from 1998-1999 and 146 selected printed canine vignettes. Its recurring clinical pattern is oxygen-carrying support used as a bridge while definitive treatment addressed the cause.
Define the window in which immediate oxygen-carrying support may bridge to hemorrhage control, surgery, disease-specific therapy, compatible blood or endogenous erythropoiesis.
PCV measures red-cell volume, not plasma hemoglobin. Total hemoglobin, circulation, unloading, tissue demand and clinical physiology must be considered together.
Canine history can define research questions. It cannot establish formulation, dose, rate, safety, efficacy or approval in another species.
Evidence boundary: descriptive, product-specific and selection-prone. The archive is separate from the controlled FDA field trial and is not evidence of BHOC efficacy. The full scan is not republished while redistribution rights remain unconfirmed.
Dog indication, FDA endpoint, product history and primary regulatory sources. Approval must not be transferred to other species or BHOC.
Cat donor-blood constraints, case literature and clearly labelled off-label or translational oxygen-carrier evidence.
Equine surgery, hemorrhage, transfusion logistics, oxygen physiology and species-specific safety questions.
Camel and camelid oxygen biology, distinctive erythrocyte physiology and evidence gaps relevant to development.
Avian respiratory physiology and evidence requirements for birds, falcons, raptors and parrots.
Zoo, wildlife, marine and endangered-species care with independent biodiversity sources and no endorsement claims.
Publication taxonomy for efficacy, dosing, NO scavenging, vasoconstriction, methemoglobin, renal and immunologic safety.
Animal blood banks, donor availability, crossmatching, storage, wastage and the multifunctional role of donor blood.
Six directly relevant historical publications with original sources. The complete bibliography remains in the central BHOC catalogue.
BHOC means Biological Hemoglobin Oxygen Carrier. It is a developing product category with an emerging evidence base, not a transferred approval claim.
Developing veterinary questions, hypotheses and pre-publication analysis kept separate from established evidence. First concept: donor welfare, feline blood donation and an additional oxygen-delivery layer.
Iron-containing heme protein and the central oxygen carrier across almost all vertebrate life.
Copper-based oxygen carrier found in many molluscs and arthropods.
Non-heme iron oxygen-binding protein found in several marine invertebrate groups.
Greenish extracellular respiratory pigment found in certain marine polychaete worms.
Large extracellular hemoglobin complex found in annelids and some other invertebrates.
A notable vertebrate exception: adult crocodile icefish lack functional hemoglobin and rely on specialized cold-water physiology.